Home LiteratureArticle Details
PMID: 22404079 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Low expression of RECK indicates a shorter survival for patients with invasive breast cancer.

Cancer science ·Vol. 103 ·No. 6 ·2012-06-00 ·Pages 1084-9

Zhang Y, Cheng S, Zhang G, Ma W, Liu Y, Zhao R, Zhang Q, Pang D

Abstract

Expression cloning was used to initially isolate the reversion-inducing cysteine-rich protein with Kazal motifs (RECK) gene as a suppressor of transformation. The gene was found to encode a membrane-anchored regulator of MMPs. Experimental studies showed that RECK can suppress tumor invasion, metastasis, and angiogenesis. However, the clinical impact of RECK remains unclear. To assess the clinical significance of RECK expression in invasive breast cancer, a total of 119 patients with invasive breast cancer were retrospectively examined. Expression of RECK in tumor tissues was assessed by immunohistochemical staining. A significant correlation between RECK expression and 5-year survival rate was documented. The 5-year survival rate for patients with strong RECK expression was significantly higher than that for patients with weakly expressing tumors. Univariate and multivariate analyses confirmed that reduced RECK expression was an independent and significant factor in predicting a poor prognosis. In conclusion, RECK expression is a significant prognostic factor correlated with long-term survival for patients with invasive breast cancer. RECK expression is therefore a potentially useful prognostic marker for breast cancer.

MeSH Terms
Adult Aged Biomarkers, Tumor/metabolism Breast Neoplasms/metabolism,mortality,pathology Female GPI-Linked Proteins/genetics,metabolism Gene Expression Regulation, Neoplastic Humans Kaplan-Meier Estimate Matrix Metalloproteinase 2/metabolism Matrix Metalloproteinase 9/metabolism Middle Aged Neoplasm Invasiveness Prognosis Receptor, ErbB-2/metabolism Survival Rate
Chemicals
Biomarkers, Tumor GPI-Linked Proteins RECK protein, human ERBB2 protein, human Receptor, ErbB-2 Matrix Metalloproteinase 2 Matrix Metalloproteinase 9
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Zhang Yue
Department of Medical Oncology, The Third Affiliated Hospital of Harbin Medical University, Harbin, China.
Cheng Shaoqiang
Zhang Guoqiang
Ma Wenjie
Liu Yang
Zhao Rui
Zhang Qingyuan
Pang Da
References (32)
32 references, click to expand
  1. MT1-MMP: a tethered collagenase.
    J Cell Physiol. 2004 Jul;200(1):11-9 PMID: 15137053
  2. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis.
    Cell. 2001 Dec 14;107(6):789-800 PMID: 11747814
  3. A prognostic index in primary breast cancer.
    Br J Cancer. 1982 Mar;45(3):361-6 PMID: 7073932
  4. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1.
    Cancer Res. 1997 Jun 15;57(12):2384-7 PMID: 9192814
  5. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK.
    Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13221-6 PMID: 9789069
  6. Tissue inhibitor of metalloproteinase-2 regulates matrix metalloproteinase-2-mediated endothelial barrier dysfunction and breast cancer cell transmigration through lung microvascular endothelial cells.
    Mol Cancer Res. 2010 Jul;8(7):939-51 PMID: 20571065
  7. The role of gelatinases in colorectal cancer progression and metastasis.
    Biochim Biophys Acta. 2004 Dec 17;1705(2):69-89 PMID: 15588763
  8. RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing--cysteine-rich protein with Kazal motifs.
    Hepatology. 2001 Jan;33(1):189-95 PMID: 11124835
  9. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer.
    Eur J Cancer. 2004 Jul;40(10):1617-23 PMID: 15196549
  10. Matrix metalloproteinases and their clinical relevance in urinary bladder cancer.
    Nat Rev Urol. 2011 May;8(5):241-54 PMID: 21487384
  11. Expression of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) as a prognostic indicator in gastric cancer.
    Eur J Cancer. 2006 Jan;42(1):101-8 PMID: 16324834
  12. RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling.
    Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):167-75 PMID: 12784995
  13. HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion.
    J Biol Chem. 2006 Feb 24;281(8):4718-25 PMID: 16377629
  14. Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis.
    Breast Cancer Res. 2000;2(6):408-16 PMID: 11250734
  15. Oncogene-mediated downregulation of RECK, a novel transformation suppressor gene.
    Braz J Med Biol Res. 1999 Jul;32(7):891-5 PMID: 10454749
  16. RECKing MMP function: implications for cancer development.
    Trends Cell Biol. 2002 May;12(5):209-11 PMID: 12062160
  17. Breast cancer progression: insights into multifaceted matrix metalloproteinases.
    Clin Exp Metastasis. 2007;24(8):647-56 PMID: 17968664
  18. Matrix metalloproteinases in cancer.
    Essays Biochem. 2002;38:21-36 PMID: 12463159
  19. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma.
    Cancer. 2003 Jun 1;97(11):2710-5 PMID: 12767082
  20. Matrix metalloproteinase-2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma.
    Hum Pathol. 2011 Jan;42(1):57-67 PMID: 20970160
  21. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry.
    Circ Res. 2003 May 2;92(8):827-39 PMID: 12730128
  22. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting.
    FEBS J. 2011 Jan;278(1):16-27 PMID: 21087457
  23. A ras-related gene with transformation suppressor activity.
    Cell. 1989 Jan 13;56(1):77-84 PMID: 2642744
  24. Characterization of a human MSX-2 cDNA and its fragment isolated as a transformation suppressor gene against v-Ki-ras oncogene.
    Oncogene. 1996 May 16;12(10):2137-46 PMID: 8668339
  25. Tumor metastasis: a new twist on epithelial-mesenchymal transitions.
    Curr Biol. 2004 Sep 7;14(17):R719-21 PMID: 15341765
  26. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis.
    Clin Cancer Res. 2003 May;9(5):1779-84 PMID: 12738734
  27. Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer.
    Cancer Lett. 2006 Jun 18;237(2):289-97 PMID: 16046057
  28. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis.
    Cell. 2004 Jun 25;117(7):927-39 PMID: 15210113
  29. MT1-MMP and RECK are involved in human CD34+ progenitor cell retention, egress, and mobilization.
    J Clin Invest. 2009 Mar;119(3):492-503 PMID: 19197139
  30. Detection of genes with a potential for suppressing the transformed phenotype associated with activated ras genes.
    Proc Natl Acad Sci U S A. 1989 Jan;86(1):162-6 PMID: 2463620
  31. RECK negatively regulates matrix metalloproteinase-9 transcription.
    Cancer Res. 2009 Feb 15;69(4):1502-8 PMID: 19208844
  32. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential.
    BMC Cancer. 2009 Jan 14;9:20 PMID: 19144199
Article Info
Journal
Cancer science
Abbr.
Cancer Sci
ISSN
1349-7006
DOI
10.1111/j.1349-7006.2012.02265.x
Published
2012-06-00
Epub
2012-00-19
Pages
1084-9
Language
English
Region
England
NLM ID
101168776
PMCID
PMC7685079
Subset
IM
External Links
PubMed source DOI: 10.1111/j.1349-7006.2012.02265.x PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2